<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035784</url>
  </required_header>
  <id_info>
    <org_study_id>A333--1</org_study_id>
    <nct_id>NCT05035784</nct_id>
  </id_info>
  <brief_title>RCE With FMT in the Treatment of Childhood Constipation</brief_title>
  <official_title>Retrograde Colonic Enema With Fecal Microbiota Transplantation vs Retrograde Colonic Enema Only in the Treatment of Childhood Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Constipation is the most common complaint in childhood gastrointestinal disease, affecting an&#xD;
      estimated 20% of the global children.The treatment strategies consist of diet control,&#xD;
      behavioral intervention and oral and sometimes rectal laxatives. Given higher success rate&#xD;
      and fewer side effects, the laxative PEG3350 has been considered the first choice in&#xD;
      childhood constipation.However, effectiveness of PEG 3350 laxative is not lasting, and the&#xD;
      use of PEG increases the risk of fecal incontinence. Additional treatment interventions are&#xD;
      still necessary.Enema can act directly on the rectum and distal colon to quickly relieve&#xD;
      symptoms of fecal impaction which is considered one of main source of intractable&#xD;
      constipation. Children with fecal impaction who received enema had fewer fecal incontinence&#xD;
      and diarrhea than children who received PEG. There have been lots of evidence that enema is&#xD;
      effective in fecal impaction in children with functional constipation.But there are still&#xD;
      cases of recurrences noted after enema. Fecal bacteria transplantation (FMT) is a new&#xD;
      treatment method emerging in recent years, which is widely used in the treatment of&#xD;
      functional gastrointestinal diseases. FMT has been proved to play a very prominent role in&#xD;
      correcting intestinal flora disorders. By transplanting exogenous flora into the intestinal&#xD;
      tract of patients, FMT can inhibit bacterial reproduction, regulate intestinal environment&#xD;
      and cascade the body immunity, so as to achieve the therapeutic effect of disease.&#xD;
&#xD;
      Retrograde colonic enema with FMT, an new method, provides the possibility for the treatment&#xD;
      of childhood constipation. However, there is still a lack of evidence-based support for the&#xD;
      treatment of childhood constipation by retrograde colonic enema with FMT. Therefore, we&#xD;
      designed a randomized, controlled, double-blind clinical trial to confirm the efficacy and&#xD;
      safety of retrograde colonic enema with FMT in the treatment of childhood constipation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2019</start_date>
  <completion_date type="Anticipated">March 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of CSBMs (sub/week) from baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>the frequency of defecation without drugs or other auxiliary methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement of CSBMs (sub/week) from baseline</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>the frequency of defecation without drugs or other auxiliary methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement of CSBMs (sub/week) from baseline</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>the frequency of defecation without drugs or other auxiliary methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with bowel function</measure>
    <time_frame>Baseline</time_frame>
    <description>Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with bowel function</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with bowel function</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel movements</measure>
    <time_frame>Baseline</time_frame>
    <description>the frequency of bowel movements per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel movements</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>the frequency of bowel movements per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel movements</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>the frequency of bowel movements per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painful or hard bowel movements</measure>
    <time_frame>Baseline</time_frame>
    <description>The feelings of children during defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painful or hard bowel movements</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>The feelings of children during defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painful or hard bowel movements</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>The feelings of children during defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large diameter or scybalous stools</measure>
    <time_frame>Baseline</time_frame>
    <description>appearance and wetness of stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large diameter or scybalous stools</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>appearance and wetness of stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large diameter or scybalous stools</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>appearance and wetness of stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excessive volitional stool retention</measure>
    <time_frame>Baseline</time_frame>
    <description>The number of children who intentionally control or reduce the frequency of defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excessive volitional stool retention</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>The number of children who intentionally control or reduce the frequency of defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excessive volitional stool retention</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>The number of children who intentionally control or reduce the frequency of defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Encopresis</measure>
    <time_frame>Baseline</time_frame>
    <description>the frequency of fecal incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Encopresis</measure>
    <time_frame>at the end of 4-weeks FMT treatment</time_frame>
    <description>the frequency of fecal incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Encopresis</measure>
    <time_frame>at the end of 12 weeks follow-up</time_frame>
    <description>the frequency of fecal incontinence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Fecal Microbiota Transplantation</condition>
  <condition>Constipation - Functional</condition>
  <arm_group>
    <arm_group_label>Fecal supernatant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fecal supernatant is used for treatment of childhood Constipation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Fecal supernatant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is used for treatment of childhood Constipation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal supernatant</intervention_name>
    <description>Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .</description>
    <arm_group_label>Fecal supernatant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.</description>
    <arm_group_label>non-Fecal supernatant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  4-14 years old;&#xD;
&#xD;
          -  Roman IV criteria for childhood constipation;&#xD;
&#xD;
          -  After a course of PEG and a course of Chinese medicine treatment was ineffective;&#xD;
&#xD;
          -  Barium enema showing fecal impaction.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Congenital and/or acquired intestinal diseases, such as congenital megacolon,&#xD;
             intestinal stenosis, polyps, Crohn's disease, tuberculosis, inflammation, and tumors;&#xD;
&#xD;
          -  Anorectal diseases, such as anal atresia, fistula, abscess, and tumor;&#xD;
&#xD;
          -  Neurological diseases, such as brain and spinal cord diseases;&#xD;
&#xD;
          -  genetic metabolic diseases;&#xD;
&#xD;
          -  psychosocial and behavioral diseases;&#xD;
&#xD;
          -  other systemic diseases;&#xD;
&#xD;
          -  Refused to participate in.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shucheng ZHANG</last_name>
    <phone>86-24-96615-57911</phone>
    <email>zhangshucheng76@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shengjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shucheng ZHANG</last_name>
      <phone>86-24-96615-57911</phone>
      <email>zhangshucheng76@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016. Review.</citation>
    <PMID>27529553</PMID>
  </reference>
  <reference>
    <citation>Gurram B, Sue PK. Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr. 2019 Oct;31(5):623-629. doi: 10.1097/MOP.0000000000000787. Review.</citation>
    <PMID>31169545</PMID>
  </reference>
  <reference>
    <citation>Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, Higgins PDR, Owyang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019 Jul;114(7):1043-1050. doi: 10.14309/ajg.0000000000000198.</citation>
    <PMID>30908299</PMID>
  </reference>
  <reference>
    <citation>Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, Wei Y, Chen Q, Zhu W, Li J, Li N. Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study. J Clin Gastroenterol. 2016 Nov/Dec;50(10):865-870.</citation>
    <PMID>26751143</PMID>
  </reference>
  <reference>
    <citation>Ohkusa T, Koido S, Nishikawa Y, Sato N. Gut Microbiota and Chronic Constipation: A Review and Update. Front Med (Lausanne). 2019 Feb 12;6:19. doi: 10.3389/fmed.2019.00019. eCollection 2019. Review.</citation>
    <PMID>30809523</PMID>
  </reference>
  <reference>
    <citation>Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019 Nov 21;381(21):2070-2072. doi: 10.1056/NEJMc1913670. Epub 2019 Oct 30.</citation>
    <PMID>31665572</PMID>
  </reference>
  <reference>
    <citation>Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002. doi: 10.1093/cid/cir632. Review.</citation>
    <PMID>22002980</PMID>
  </reference>
  <reference>
    <citation>Vriesman MH, Koppen IJN, Camilleri M, Di Lorenzo C, Benninga MA. Management of functional constipation in children and adults. Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):21-39. doi: 10.1038/s41575-019-0222-y. Epub 2019 Nov 5. Review.</citation>
    <PMID>31690829</PMID>
  </reference>
  <reference>
    <citation>Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016 Sep 28;22(36):8078-93. doi: 10.3748/wjg.v22.i36.8078. Review.</citation>
    <PMID>27688650</PMID>
  </reference>
  <reference>
    <citation>Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27. Review.</citation>
    <PMID>28129018</PMID>
  </reference>
  <reference>
    <citation>Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017 Mar;46(1):171-185. doi: 10.1016/j.gtc.2016.09.012. Review.</citation>
    <PMID>28164849</PMID>
  </reference>
  <reference>
    <citation>Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, Tan B, Wang XY. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018 Jan 7;24(1):5-14. doi: 10.3748/wjg.v24.i1.5. Review.</citation>
    <PMID>29358877</PMID>
  </reference>
  <reference>
    <citation>Dai M, Liu Y, Chen W, Buch H, Shan Y, Chang L, Bai Y, Shen C, Zhang X, Huo Y, Huang D, Yang Z, Hu Z, He X, Pan J, Hu L, Pan X, Wu X, Deng B, Li Z, Cui B, Zhang F. Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. Crit Care. 2019 Oct 21;23(1):324. doi: 10.1186/s13054-019-2604-5.</citation>
    <PMID>31639033</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Shucheng Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

